{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:05:23Z","timestamp":1790593523909,"version":"4.1.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Intravesical administration is a standard application route for the treatment of non-muscle-invasive bladder cancer, as it allows for high drug concentrations near tumor sites while largely avoiding systemic exposure and associated adverse effects. However, the efficacy can be constrained by the urothelium's strong barrier properties, as well as continuous dilution and elimination of drugs through urine production and voiding. Bladder-retentive drug delivery systems, such as intravesical sustained-release formulations that accumulate therapeutics at the bladder wall or active targeting to tumor cells may address these limitations. In this context, mucoadhesive formulations are promising because they resist urinary washout, extend dwell time, and enhance urothelial drug deposition. Targeted delivery platforms can increase drug load within malignant tissues and may even accelerate onset of pharmacologic activity via receptor mediated pathways. If binding to tumor-specific target structures also modulates the disease itself, active targeting can extend beyond pharmacokinetic benefits to integrate different pharmacodynamic mechanisms, thereby contributing to more precise and effective cancer therapy. Several targeted intravesical drug formulations, including antibody-drug conjugates against tumor associated antigens, integrin directed systems, hyaluronic acid\u2013based CD44 targeted constructs, as well as immunomodulatory agents, have advanced to clinical or late preclinical evaluation. The intravesical route further provides an opportunity to repurpose drugs originally developed for systemic use but limited by off target toxicities that are unlikely to be dose limiting with local intravesical administration. This mini review provides an overview of intravesical, bladder-retentive systems for treating urothelial carcinoma, with a particular emphasis on recent developments in tumor-targeted intravesical precision medicines.<\/jats:p>","DOI":"10.3389\/fmed.2026.1979620","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:39:39Z","timestamp":1790591979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies"],"prefix":"10.3389","volume":"13","author":[{"given":"Hatixhe","family":"Sahini","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Vienna","place":["Vienna, Austria"]},{"name":"Vienna Doctoral School of Pharmaceutical, Nutritional and Sport Sciences, University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Anzengruber","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"L\u00e4chelt","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"Br Med J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.6004\/jnccn.2026.0022","article-title":"Bladder cancer, version 1.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Flaig","year":"2026","journal-title":"J Natl Compr Cancer Network"},{"key":"B4","year":"2014"},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2025.02.010","article-title":"A systematic review of novel intravesical approaches for the treatment of patients with non\u2013muscle-invasive bladder cancer","volume":"88","author":"Ghodoussipour","year":"2025","journal-title":"Eur Urol"},{"key":"B6","year":"2025"},{"key":"B7","year":"2020"},{"key":"B8","year":"2023"},{"key":"B9","year":"2024"},{"key":"B10","year":"2025"},{"key":"B11","year":"2024"},{"key":"B12","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY-PanTumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-023-01475-9","article-title":"Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU cancers symposium","volume":"16","author":"Yu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/pharmaceutics13020166","article-title":"Strategies to get drugs across bladder penetrating barriers for improving bladder cancer therapy","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/1078-0432.Ccr-14-0913","article-title":"The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity","volume":"21","author":"Mangsbo","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"F867","DOI":"10.1152\/ajprenal.2000.278.6.F867","article-title":"Everything you wanted to know about the bladder epithelium but were afraid to ask","volume":"278","author":"Lewis","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J Control Release"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry: jain, smith, ghone and tomczuk","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/adhm.201500344","article-title":"Self-immolative linkers literally bridge disulfide chemistry and the realm of thiol-free drugs","volume":"4","author":"Riber","year":"2015","journal-title":"Adv Healthcare Mater"},{"key":"B21","first-page":"3","article-title":"Tight junctions and bladder cancer (review)","volume":"16","author":"Haynes","year":"2005","journal-title":"Int J Mol Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jconrel.2023.01.001","article-title":"Mechanisms and strategies to enhance penetration during intravesical drug therapy for bladder cancer","volume":"354","author":"Zhang","year":"2023","journal-title":"J Control Release"},{"key":"B23","doi-asserted-by":"publisher","first-page":"124957","DOI":"10.1016\/j.ijbiomac.2023.124957","article-title":"Mucoadhesive gellan gum-based and carboxymethyl cellulose -based hydrogels containing gemcitabine and papain for bladder cancer treatment","volume":"242","author":"de Lima","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3390\/pharmaceutics14112527","article-title":"Quercetin loaded cationic solid lipid nanoparticles in a mucoadhesive in situ gel-A novel intravesical therapy tackling bladder cancer","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.11.031","article-title":"Urothelium-adherent, ion-triggered liposome-in-gel system as a platform for intravesical drug delivery","volume":"245","author":"GuhaSarkar","year":"2017","journal-title":"J Control Release"},{"key":"B26","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.2147\/IJN.S93750","article-title":"Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan\u2013thioglycolic acid nanoparticles and comparison of chitosan\/poloxamer gels as carriers","volume":"10","author":"Ay \u015eenyi\u011fit","year":"2015","journal-title":"Int J Nanomed"},{"key":"B27","first-page":"100007","article-title":"Chitosan\/\u03b2-glycerophosphate in situ gelling mucoadhesive systems for intravesical delivery of mitomycin-C","volume":"1","author":"Kolawole","year":"2019","journal-title":"International Journal of Pharmaceutics: X"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1800004","DOI":"10.1002\/advs.201800004","article-title":"Mucoadhesive cationic polypeptide nanogel with enhanced penetration for efficient intravesical chemotherapy of bladder cancer","volume":"5","author":"Guo","year":"2018","journal-title":"Advanced Science"},{"key":"B29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41578-024-00766-y","article-title":"Delivering living medicines with biomaterials","volume":"10","author":"Harimoto","year":"2025","journal-title":"Nature Reviews Materials"},{"key":"B30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.tibtech.2019.12.012","article-title":"Intravesical hydrogels as drug reservoirs","volume":"38","author":"Qiu","year":"2020","journal-title":"Trends Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100439","DOI":"10.1016\/j.grets.2026.100439","article-title":"Sustainable hydrogel platforms for local tumor therapy: from rational design to clinical translation","volume":"4","author":"Xu","year":"2026","journal-title":"Green Technologies and Sustainability"},{"key":"B32","doi-asserted-by":"publisher","first-page":"103182","DOI":"10.1016\/j.jddst.2022.103182","article-title":"Contemporary applications of thermogelling PEO-PPO-PEO triblock copolymers","volume":"70","author":"Mfoafo","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"key":"B33","year":"2025"},{"key":"B34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/ju.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION)","volume":"213","author":"Prasad","year":"2025","journal-title":"J Urol"},{"key":"B35","year":"2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2200211","DOI":"10.1002\/admi.202200211","article-title":"Recent advances in mucoadhesive interface materials, mucoadhesion characterization, and technologies","volume":"9","author":"Bayer","year":"2022","journal-title":"Adv Mater Interfaces"},{"key":"B37","doi-asserted-by":"publisher","first-page":"116528","DOI":"10.1016\/j.carbpol.2020.116528","article-title":"Chitosan-coated nanodiamonds: mucoadhesive platform for intravesical delivery of doxorubicin","volume":"245","author":"Ali","year":"2020","journal-title":"Carbohydr Polym"},{"key":"B38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejps.2016.01.013","article-title":"Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer","volume":"84","author":"Lu","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jconrel.2020.03.028","article-title":"Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer","volume":"324","author":"Xu","year":"2020","journal-title":"J Controlled Release"},{"key":"B40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.actbio.2016.07.025","article-title":"Spray-dried mucoadhesives for intravesical drug delivery using N-acetylcysteine- and glutathione-glycol chitosan conjugates","volume":"43","author":"Denora","year":"2016","journal-title":"Acta Biomater"},{"key":"B41","doi-asserted-by":"publisher","first-page":"138412","DOI":"10.1016\/j.ijbiomac.2024.138412","article-title":"Chitosan\/polyvinyl alcohol-based magnetic hydrogel microspheres with controlled retention and regulated drug release for intravesical instillation","volume":"287","author":"Yin","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.juro.2010.11.091","article-title":"Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy","volume":"185","author":"Lu","year":"2011","journal-title":"J Urol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"110832","DOI":"10.1016\/j.colsurfb.2020.110832","article-title":"Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy","volume":"189","author":"Wang","year":"2020","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejpb.2019.08.007","article-title":"Maleimide-functionalised PLGA-PEG nanoparticles as mucoadhesive carriers for intravesical drug delivery","volume":"143","author":"Kaldybekov","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejps.2017.09.039","article-title":"Mucoadhesive maleimide-functionalised liposomes for drug delivery to urinary bladder","volume":"111","author":"Kaldybekov","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"eaeb9764","DOI":"10.1126\/sciadv.aeb9764","article-title":"Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer","volume":"12","author":"Zhao","year":"2026","journal-title":"Sci Adv"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11051-024-06199-6","article-title":"Recent advances and FDA approvals in nanoformulations for drug delivery","volume":"27","author":"Asadi","year":"2025","journal-title":"J Nanopart Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/pharmaceutics15010211","article-title":"The progress of chitosan-based nanoparticles for intravesical bladder cancer treatment","volume":"15","author":"Yu","year":"2023","journal-title":"Pharmaceutics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1021\/acs.jmedchem.4c00060","article-title":"A selective-tumor-penetrating strategy via unidirectional direct transfer for intravesical therapy of bladder cancer","volume":"67","author":"Qin","year":"2024","journal-title":"J Med Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","article-title":"Ligand-targeted drug delivery","volume":"117","author":"Srinivasarao","year":"2017","journal-title":"Chem Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1063\/1.5052455","article-title":"Physics in nanomedicine: phenomena governing the in vivo performance of nanoparticles","volume":"7","author":"Lane","year":"2020","journal-title":"Applied Physics Reviews"},{"key":"B52","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12951-026-04284-7","article-title":"A \u2018two-in-one\u2019 tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues","volume":"24","author":"Qin","year":"2026","journal-title":"J Nanobiotechnol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.Cd-26-0099","article-title":"A spatial atlas of muscle-invasive bladder cancer reveals lineage-specific vulnerabilities and immune architecture","author":"Yu","year":"2026","journal-title":"Cancer Discov"},{"key":"B54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bju.16643","article-title":"Spatial distribution and subtype-specific expression patterns of nectin-4 in muscle-invasive bladder cancer","volume":"136","author":"Olah","year":"2025","journal-title":"BJU Int"},{"key":"B55","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/pharmaceutics18030386","article-title":"Receptor-mediated drug delivery: redefining targeted drug conjugates in oncology","volume":"18","author":"Jafari","year":"2026","journal-title":"Pharmaceutics"},{"key":"B56","author":"Agency","year":"2026"},{"key":"B57","year":"2024"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/cancers16061195","article-title":"CD44 in bladder cancer","volume":"16","author":"Duex","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"13108","DOI":"10.1038\/s41598-026-42566-0","article-title":"CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer","volume":"16","author":"Lodewijk","year":"2026","journal-title":"Sci Rep"},{"key":"B61","year":"2021"},{"key":"B62","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/01.JU.0001109740.05294.af.14","article-title":"IP02-14 PHASE III, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVESICAL PACLITAXEL-HYALURONIC ACID CONJUGATE IN PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA in situ OF THE BLADDER+\/-ta-T1 PAPILLARY DISEASE (ORION-BC STUDY)","volume":"213","author":"Kates","year":"2025","journal-title":"J Urol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"52374","DOI":"10.1021\/acsami.1c14944","article-title":"Intravesical mucoadhesive hydrogel induces chemoresistant bladder cancer ferroptosis through delivering iron oxide nanoparticles in a three-tier strategy","volume":"13","author":"Qi","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"B64","doi-asserted-by":"publisher","first-page":"46668","DOI":"10.1021\/acsami.3c09564","article-title":"Hyaluronic acid-conjugated fluorescent probe-shielded polydopamine nanomedicines for targeted imaging and chemotherapy of bladder cancer","volume":"15","author":"Qiu","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fphar.2022.1043283","article-title":"Ferroptosis: a new therapeutic target for bladder cancer","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.urolonc.2005.08.020","article-title":"HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer","volume":"24","author":"Rosato","year":"2006","journal-title":"Urol Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.urolonc.2012.01.005","article-title":"Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines","volume":"31","author":"Montagner","year":"2013","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1007\/s11255-026-05110-7","article-title":"Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis","volume":"58","author":"Guo","year":"2026","journal-title":"Int Urol Nephrol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B70","year":"2025"},{"key":"B71","year":"2025"},{"key":"B72","year":"2023"},{"key":"B73","year":"2025"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e2302377","DOI":"10.1002\/advs.202302377","article-title":"A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B75","year":"2024"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e70288","DOI":"10.1002\/mco2.70288","article-title":"Intravesical disitamab vedotin (RC48) for HER2-expressing high-risk non-muscle-invasive bladder cancer: a single-arm, dose-escalation phase I trial study","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm (2020)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12935-026-04210-9","article-title":"The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor","volume":"26","author":"Ye","year":"2026","journal-title":"Cancer Cell Int"},{"key":"B78","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"105067","DOI":"10.1016\/j.critrevonc.2025.105067","article-title":"Antibody-drug conjugates in urothelial, prostate, and renal cell cancers: a review of current and emerging therapies","volume":"218","author":"Perera","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B80","year":"2024"},{"key":"B81","doi-asserted-by":"publisher","first-page":"TPS4627","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4627","article-title":"Intravesical sacituzumab tirumotecan in participants with intermediate-risk non\u2013muscle-invasive bladder cancer: the phase 1\/2 TroFuse-027 study","volume":"43","author":"Meeks","year":"2025","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"498.e1","DOI":"10.1016\/j.urolonc.2021.04.011","article-title":"Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma","volume":"39","author":"Todenh\u00f6fer","year":"2021","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"B83","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.eururo.2015.06.015","article-title":"Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer","volume":"68","author":"de Martino","year":"2015","journal-title":"Eur Urol"},{"key":"B84","year":"2025"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3390\/cancers17071190","article-title":"Preclinical and clinical feasibility studies as the first step before forthcoming intravesical instillation of [(211)At]at-anti-CA-IX antibody (ATO-101\u2122) study in patients with non-muscle-invasive bladder cancer unresponsive to standard of care","volume":"17","author":"Rousseau","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B86","year":"2025"},{"key":"B87","doi-asserted-by":"publisher","first-page":"103893","DOI":"10.1016\/j.drudis.2024.103893","article-title":"A potential novel cancer immunotherapy: agonistic anti-CD40 antibodies","volume":"29","author":"Jian","year":"2024","journal-title":"Drug Discov Today"},{"key":"B88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1096-9896(199905)188:1<38::AID-PATH315>3.0.CO;2-B","article-title":"CD40 expression in bladder cancer","volume":"188","author":"Cooke","year":"1999","journal-title":"J Pathol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1158\/1078-0432.Ccr-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma\u2013the first phase I\/IIa trial","volume":"16","author":"Malmstr\u00f6m","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B92","year":"2021"},{"key":"B93","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.urolonc.2024.12.240","article-title":"CORRELATIVE SCIENCE FROM A PHASE I STUDY OF INTRAVESICAL FC-OPTIMIZED ANTI-CD40 AGONIST ANTIBODY 2141-V11 FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)","volume":"43","author":"Bochner","year":"2025","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e19328","DOI":"10.7717\/peerj.19328","article-title":"Integrin signaling in tumor biology: mechanisms of intercellular crosstalk and emerging targeted therapies","volume":"13","author":"Li","year":"2025","journal-title":"PeerJ"},{"key":"B95","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","article-title":"Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B96","doi-asserted-by":"publisher","first-page":"113745","DOI":"10.1016\/j.biopha.2022.113745","article-title":"Integrin-mediated cancer progression as a specific target in clinical therapy","volume":"155","author":"Chen","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"B97","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1535-7163.MCT-26-0077","article-title":"An integrin \u03b26-targeted antibody-drug conjugate optimized for intravesical delivery to treat non-muscle invasive bladder cancer","author":"Carosino","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"B98","year":"2025"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/mto.2016.4","article-title":"Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer","volume":"3","author":"Tsuji","year":"2016","journal-title":"Molecular Therapy - Oncolytics"},{"key":"B100","year":"2019"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/17435889.2026.2674162","article-title":"A phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non\u2013muscle-invasive bladder cancer","volume":"21","author":"Narayan","year":"2026","journal-title":"Nanomedicine"},{"key":"B102","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.urolonc.2010.06.011","article-title":"Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach","volume":"30","author":"Zhang","year":"2012","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"B103","year":"2022"},{"key":"B104","year":"2023"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1979620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:39:41Z","timestamp":1790591981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1979620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":104,"alternative-id":["10.3389\/fmed.2026.1979620"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1979620","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1979620"}}